IMRX

Immuneering Corporation [IMRX] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

IMRX Stock Summary

Top 10 Correlated ETFs

IMRX


Top 10 Correlated Stocks

IMRX


In the News

02:19 28 Mar 2024 IMRX

Immuneering: Phase 1 Data Release IMM-1-104 Leads To Additional 2024 Milestone

Positive safety and anti-tumor activity released from phase 1 portion of phase 1/2a study, using IMM-1-104 for the treatment of patients with RAS-mutant solid tumors. Additional expansion cohort results from the phase 2 portion of the phase 1/2a study, using IMM-1-104 for the treatment of patients with RAS-mutant solid tumors, expected later in 2024. IMM-6-415 is another MAPK pathway targeting drug, but is able to target either RAS or RAF solid tumors; Dosing of first patient in phase 1 study expected in March 2024.

12:06 28 Mar 2024 IMRX

Immuneering (IMRX) Plummets 71% in One Week: Here's Why

Immuneering (IMRX) plunges after multiple Wall Street analysts downgraded the stock on lackluster results from an early-stage study evaluating its lead drug across advanced RAS-mutant solid tumors.

05:00 28 Mar 2024 IMRX

Immuneering to Present Preclinical Data on Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2024

CAMBRIDGE, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, announced today that it will be presenting preclinical data on its lead program IMM-1-104 at the American Association for Cancer Research (AACR) annual meeting, held April 5-10 in San Diego, California.

08:00 28 Mar 2024 IMRX

Immuneering Announces Participation in February Investor Conferences

CAMBRIDGE, Mass., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop universal-RAS/RAF medicines for broad populations of cancer patients, today announced that management will participate in two February investor conferences to discuss the company's pipeline, platform and business strategy. Participating will be Ben Zeskind, Ph.D., Co-Founder and Chief Executive Officer, Brett Hall, Ph.D., Chief Scientific Officer, Harold “E.B.” Brakewood, Chief Business Officer, and Mallory Morales, CPA, Chief Accounting Officer, Treasurer.

04:05 28 Mar 2024 IMRX

Immuneering to Present at the 35th Annual Piper Sandler Healthcare Conference

CAMBRIDGE, Mass., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy, today announced that management will present at the 35th Annual Piper Sandler Healthcare Conference to discuss the company's pipeline, platform, and business strategy. Participating will be Ben Zeskind, Ph.D., Co-Founder and Chief Executive Officer, Brett Hall, Ph.D., Chief Scientific Officer, Harold “E.B.” Brakewood, Chief Business Officer, and Mallory Morales, CPA, Chief Accounting Officer, Treasurer.

04:05 28 Mar 2024 IMRX

Immuneering to Present Preclinical Data on IMM-1-104 and IMM-6-415 at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

CAMBRIDGE, Mass., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company developing medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy, today announced that it will present preclinical data on IMM-1-104, its lead clinical-stage program, and IMM-6-415 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, being held October 11-15, 2023 in Boston.

08:00 28 Mar 2024 IMRX

Immuneering to Present at the Morgan Stanley Healthcare Conference

CAMBRIDGE, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company developing medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy, today announced that management will present at the Morgan Stanley Healthcare Conference to discuss the company's pipeline, platform, and business strategy. Participating will be Ben Zeskind, Ph.D., Co-Founder and Chief Executive Officer, Scott Barrett, M.D., Chief Medical Officer, Brett Hall, Ph.D., Chief Scientific Officer, and Mallory Morales, CPA, Chief Accounting Officer and Treasurer.

05:55 28 Mar 2024 IMRX

Immuneering Corp.: Early Stage Promise, But Long-Term Investment

IMRX is an early-stage company with promising science. They do not have clinical efficacy data. While I like the company, be warned that this is going to take time.

11:32 28 Mar 2024 IMRX

Wall Street Analysts Think Immuneering Corporation (IMRX) Could Surge 103.8%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 103.8% in Immuneering Corporation (IMRX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

08:00 28 Mar 2024 IMRX

Immuneering to Present at the Jefferies Healthcare Conference

CAMBRIDGE, Mass., May 30, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company developing medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy, today announced that management will present at the Jefferies Healthcare Conference to discuss the company's pipeline, platform, and business strategy. Participating will be Ben Zeskind, Ph.D., Co-Founder and Chief Executive Officer, Scott Barrett, M.D., Chief Medical Officer, Brett Hall, Ph.D., Chief Scientific Officer, and Mallory Morales, CPA, Vice President of Finance, Treasurer.

IMRX Financial details

Company Rating
Neutral
Market Cap
74.67M
Income
1.02B
Revenue
94.42M
Book val./share
3.09
Cash/share
2.93
Dividend
-
Dividend %
-
Employees
68
Optionable
No
Shortable
Yes
Earnings
07 May 2024
P/E
0.19
Forward P/E
-1.31
PEG
-0
P/S
2.08
P/B
1.89
P/C
0.83
P/FCF
-3.99
Quick Ratio
17.3
Current Ratio
17.89
Debt / Equity
0.05
LT Debt / Equity
0.05
-
-
EPS (TTM)
38.78
EPS next Y
-1.86
EPS next Q
-0.49
EPS this Y
0.53%
EPS next Y
-104.8%
EPS next 5Y
-103.05%
EPS last 5Y
14.87%
Revenue last 5Y
-100%
Revenue Q/Q
-
EPS Q/Q
20.93%
-
-
-
-
SMA20
-50%
SMA50
-50%
SMA100
-50%
Inst Own
37.39%
Inst Trans
0.57%
ROA
900%
ROE
960%
ROC
-0.52%
Gross Margin
-67%
Oper. Margin
-59%
Profit Margin
1085%
Payout
-
Shs Outstand
29.28M
Shs Float
21.03M
-
-
-
-
Target Price
20.67
52W Range
1.9-14.29
52W High
-82.64%
52W Low
+143%
RSI
27
Rel Volume
1.32
Avg Volume
516.74K
Volume
682.4K
Perf Week
-5.45%
Perf Month
-62.5%
Perf Quarter
-67.43%
Perf Half Y
-67.51%
-
-
-
-
Beta
-0.747
-
-
Volatility
0.14%, 1.86%
Prev Close
0%
Price
2.43
Change
0.41%

IMRX Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric History 2019-12-312020-12-312021-12-312022-12-31 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
0.220.170.150.010
Net income per share
-0.94-1.26-2.46-1.87-1.88
Operating cash flow per share
-0.52-1.08-2.27-1.67-1.72
Free cash flow per share
-0.52-1.09-2.27-1.7-1.74
Cash per share
1.612.7510.9643.01
Book value per share
-0.76-1.6611.464.163.19
Tangible book value per share
-0.76-1.6610.933.892.94
Share holders equity per share
-0.76-1.6611.464.163.19
Interest debt per share
1.980.050.390.220.16
Market cap
150.9M237.67M220.12M127.98M208.86M
Enterprise value
153.73M201.2M150.59M60.18M153.92M
P/E ratio
-18.72-13.95-6.56-2.6-3.91
Price to sales ratio
78.61102.82105.83403.770
POCF ratio
-33.97-16.26-7.13-2.9-4.27
PFCF ratio
-33.81-16.2-7.12-2.85-4.24
P/B Ratio
-23.12-10.571.411.172.31
PTB ratio
-23.12-10.571.411.172.31
EV to sales
80.0887.0472.4189.870
Enterprise value over EBITDA
-20.94-11.86-4.44-1.16-2.67
EV to operating cash flow
-34.61-13.76-4.88-1.36-3.14
EV to free cash flow
-34.45-13.71-4.87-1.34-3.12
Earnings yield
-0.05-0.07-0.15-0.39-0.26
Free cash flow yield
-0.03-0.06-0.14-0.35-0.24
Debt to equity
-2.55-0.030.030.040.05
Debt to assets
1.180.020.030.040.04
Net debt to EBITDA
-0.392.152.051.310.95
Current ratio
27.8316.7327.0413.511.35
Interest coverage
-17.9100-51.010
Income quality
0.580.860.920.870.92
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
1.411.353.9849.240
Research and developement to revenue
2.236.4912.76114.420
Intangibles to total assets
000.040.060.07
Capex to operating cash flow
0000.020.01
Capex to revenue
-0.01-0.02-0.03-2.340
Capex to depreciation
-1.14-0.67-0.38-0.93-0.97
Stock based compensation to revenue
0.310.470.8712.820
Graham number
4.016.8725.213.2311.62
ROIC
-0.650.8-0.2-0.42-0.59
Return on tangible assets
-0.57-0.44-0.21-0.43-0.56
Graham Net
-0.78-1.7310.193.532.59
Working capital
13.56M35.48M146.7M100.69M81.24M
Tangible asset value
-6.53M-22.48M148.84M102.75M83.51M
Net current asset value
-6.56M-23.17M141.61M96.23M77.08M
Invested capital
-2.55-0.030.030.040.05
Average receivables
0355.03K373.08K129.23K6.21K
Average payables
0887.74K1.44M2.27M2.63M
Average inventory
0000.50.5
Days sales outstanding
39.9278.9743.1814.30
Days payables outstanding
88.03422.08441.377.28K1.01K
Days of inventory on hand
00000
Receivables turnover
9.144.628.4525.530
Payables turnover
4.150.860.830.050.36
Inventory turnover
000158.12K0
ROE
1.240.76-0.22-0.45-0.59
Capex per share
000-0.03-0.01

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric History 2022-12-312023-03-312023-06-302023-09-30 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
003.300
Net income per share
-0.4740.16-0.43-0.43-0.52
Operating cash flow per share
-0.44-0.55-0.38-0.41-0.4
Free cash flow per share
-0.45-0.55-0.38-0.41-0.41
Cash per share
43.463.83.322.93
Book value per share
4.163.74.023.553.09
Tangible book value per share
3.893.433.773.312.85
Share holders equity per share
4.163.74.023.553.09
Interest debt per share
0.2-40.490.160.160.15
Market cap
128.07M256.75M290.49M224.77M215.13M
Enterprise value
60.28M184.07M191.11M161.27M160.19M
P/E ratio
-2.560.06-5.96-4.46-3.57
Price to sales ratio
280.86K03.0800
POCF ratio
-10.9-17.81-27.03-18.69-18.27
PFCF ratio
-10.84-17.77-26.81-18.6-18.01
P/B Ratio
1.172.632.522.162.38
PTB ratio
1.172.632.522.162.38
EV to sales
132.19K02.0200
Enterprise value over EBITDA
-4.31-12.7-14.16-0.01-9.88
EV to operating cash flow
-5.13-12.77-17.78-13.41-13.6
EV to free cash flow
-5.1-12.74-17.64-13.35-13.41
Earnings yield
-0.14.14-0.04-0.06-0.07
Free cash flow yield
-0.09-0.06-0.04-0.05-0.06
Debt to equity
0.040.050.040.040.05
Debt to assets
0.040.040.040.040.04
Net debt to EBITDA
4.855.027.3603.39
Current ratio
13.517.0520.3517.8911.35
Interest coverage
-27.090.01000
Income quality
0.891.060.880.950.78
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
9.01K00.0400
Research and developement to revenue
21.65K00.100
Intangibles to total assets
0.060.070.060.060.07
Capex to operating cash flow
0.0100.0100.01
Capex to revenue
-151.980000
Capex to depreciation
-0.37-0.154.29-0.67-1.76
Stock based compensation to revenue
2.3K00.0100
Graham number
6.6657.86.25.875.99
ROIC
-0.1110.68-0.1-0.12-0.16
Return on tangible assets
-0.1110.55-0.1-0.12-0.16
Graham Net
3.523.093.462.992.52
Working capital
100.69M88.71M106.03M94.96M81.24M
Tangible asset value
102.75M90.7M108.02M96.94M83.51M
Net current asset value
96.23M84.33M101.72M90.72M77.08M
Invested capital
0.040.050.040.040.05
Average receivables
41.3K6.73K52300
Average payables
2.75M2.94M2.71M2.32M2.03M
Average inventory
0.50.5000
Days sales outstanding
2.45K0000
Days payables outstanding
1.81.29K1.25K892.31.03K
Days of inventory on hand
00000
Receivables turnover
0.040000
Payables turnover
50.070.070.070.10.09
Inventory turnover
157.96M0000
ROE
-0.1110.86-0.11-0.12-0.17
Capex per share
0000-0.01

IMRX Frequently Asked Questions

What is Immuneering Corporation stock symbol ?

Immuneering Corporation is a US stock , located in Cambridge of Ma and trading under the symbol IMRX

Is Immuneering Corporation buy or a sell ?

3 stock analysts have 3 predictions with a medium analyst target price of $20.67. The lowest prediction is $3 and the highest is $41

What is IMRX stock prediction ?

With a median analyst target price of $3, 1 stock analysts have made 1 forecasts in last 90 days. $3 is the lowest and $3 is the greatest projection.

What is Immuneering Corporation stock quote today ?

Immuneering Corporation stock price is $2.43 today.

Is Immuneering Corporation stock public?

Yes, Immuneering Corporation is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap